Section 13
Investment Thesis
$22K self-funded to build the Function Health of treatment
TL;DR
This business needs $22K to start — not millions. Website/app vibe-coded with AI at near-zero cost. The compound reinvestment model means every dollar of gross profit goes back into ads, and payback period is under 1 month. Year 1: $2-5M revenue (base case $3.5M). This is the same math Medvi used to reach $401M Y1 with $130-170M marketing spend. Function Health reached a $2.5B valuation with 100K members paying $365/year — we offer everything they do PLUS treatment AND pre-filled pens (nobody else has them). Gender-inclusive from day 1 (Hims started men-only, added Hers, reached $2.4B). By Year 5, we target $80-150M revenue and $16-37M profit with 100% founder ownership. If we ever raise money, it's a strategic choice (own pharmacy to cut costs), not a survival need.
Initial Capital
$22K
Break-even
Month 4-5
Year 5 Revenue
$80-150M
Year 5 Profit
$16-37M
BioForge is a self-funded longevity platform for adults 30-55 serious about health optimization. Built on the Medvi-proven infrastructure (telehealth-as-a-service) but with ethics, compliance, and a better product: pre-filled pens for specialty peptides (NOBODY else offers this). Gender-inclusive from day 1 — Hims started men-only, added Hers, reached $2.4B. We capture the full market immediately. No VC, no dilution, no burn rate pressure. $22K in (vibe-coded tech = near-zero website/app cost), break-even by month 4-5. THE COMPOUND REINVESTMENT MODEL: Initial $13K marketing budget (from $22K after setup costs) compounds because payback period is under 1 month. At $350 CAC, each new customer generates $565 in month 1 (blood work $365 + 50% convert to peptides at $400/mo). After COGS (~$260), that's $305 gross profit per customer — paying back the $350 CAC almost immediately. Every dollar in ads returns $1.60+ in the same month. This is how Medvi reached $401M Y1 with $130-170M marketing spend. Same math, same infrastructure, but with ethics and a better product. The key comparable: Function Health reached a $2.5B valuation with 100K members paying $365/year for blood tests — but they CANNOT treat what they find. BioForge offers testing AND treatment. Blood work at $365 one-time (includes first consultation + protocol recommendation) is the funnel. Then peptide subscriptions at $299-999/month. Why this works without external capital: 1. Medvi proved $20K is enough — telehealth infrastructure is plug-and-play 2. Vibe coding with AI = near-zero tech cost. $22K covers everything. 3. Compound reinvestment: $5K ad spend month 1 grows to $750K by month 12, all from reinvested gross profit 4. Blood work at $365 (cost $180) + 50% peptide conversion = payback under 1 month per customer 5. Pre-filled pens = first mover advantage with 2-3x pricing premium (Zepbound pen = $1,086 vs vial = $349-499) 6. Wholesale peptide costs are shockingly low: BPC-157 = $18, CJC+Ipamorelin = $27, semaglutide = $21. Margins 55-85%. 7. Year 1: $2-5M revenue (base case $3.5M), $1.9M marketing spend, ~$910K net profit 8. Year 5: $80-150M revenue (base case $100M), 20-25% net margin 9. Dubai 0% tax means every dollar of profit compounds faster 10. Business isn't always math — we use ranges because real-world variables create variance Optional future capital ($2-3M at $10M+ revenue) ONLY if choosing to vertically integrate: - Own 503B pharmacy license drops COGS from 25% to 10% - This is a strategic choice, not a survival need - $5-50K/year concierge tiers added in Year 2-3 roadmap, not at launch
Funding Requirements
Amount
$22,000
Instrument
Self-funded (founder capital)
Valuation Cap
N/A — no external investors at launch
Runway
4-5 months to break-even, then compound reinvestment from revenue
Use of Funds
Return Scenarios (5-Year)
Y5 Revenue
$80M
Y5 Net Profit
$16M
Implied Valuation
N/A — private cash-cow business
ROI on $500K
$16M/year profit on $22K invested. 700x+ cumulative return.
Lower ad efficiency, higher churn, US only. Year 1: $2M revenue. Still compounds because payback period stays under 2 months.
Y5 Revenue
$100M
Y5 Net Profit
$23M
Implied Valuation
$300M (3x revenue) if ever sold
ROI on $500K
$23M/year profit on $22K invested. 1,000x+ cumulative return.
Compound reinvestment model, US + UAE, 10 peptides + pre-filled pens. Year 1: $3.5M revenue. Ad spend compounds from $5K to $750K/month.
Y5 Revenue
$150M
Y5 Net Profit
$37M
Implied Valuation
$450-600M (3-4x revenue)
ROI on $500K
$37M/year profit. Raise $2-3M at Year 3 for own pharmacy — 72% gross margin.
Full compound reinvestment + own 503B pharmacy at Year 3. COGS drops from 25% to 10%. Multi-market. Pre-filled pen dominance.
Exit Strategy
Profitable Private Company (Default Path)
Following the Medvi/Gallagher model — remain private, extract profits, no exit needed. At $100M revenue and 23% net margin, that's $23M/year in profit with 100% founder ownership. No investors to answer to.
Strategic Acquisition (If the Price is Right)
At $100M+ revenue with a strong brand, acquisition by Hims, Ro, GoodRx, or a PE firm becomes attractive. Only sell if the offer is life-changing (3-5x revenue = $300-500M).
Vertical Integration & Scale
Raise $2-3M at $10M+ revenue to acquire/build a 503B compounding pharmacy. COGS drops from 25% to 10%, margin jumps dramatically. This is a growth accelerator, not a survival need.
Private Equity Buyout
PE firms love profitable DTC health brands with recurring revenue. At 23% net margin and $100M revenue, BioForge is a PE dream. Sell 60-80% while retaining operational control.
Milestone-Based Funding
Company Formation
Dubai free zone LLC, US entity, telehealth partner agreement
$7KProduct Launch
Website live, 3 peptides (BPC-157, CJC-1295+Ipamorelin, semaglutide), first paid ads
$10KFirst 100 Customers
Product-market fit validated. Compound reinvestment loop proven. Ad spend compounding.
$5KBreak-even (Month 4-5)
Profitable on monthly basis. ~500 customers. Ad spend growing to $23K+/month from reinvested profits.
$2-5M Revenue / Year 1
1,500-2,500 subscribers. $1.9M total marketing spend. Compound reinvestment model proven. Pre-filled pen partnerships established.
$10-20M Revenue / Year 2
4,000-7,000 subscribers. First hire. Add concierge tiers ($5-10K/year). UAE market prep.
$25-50M Revenue / Year 3
8,000-14,000 subscribers. Add Elite tier ($25-50K/year). Decision: raise capital for own pharmacy or stay lean.
$80-150M Revenue / Year 5
20,000-35,000 subscribers, 20-25% net margin, $16-37M annual profit
Why Now
- 1Regulatory window: FDA peptide reclassification creates time-limited first-mover advantage
- 2Proven model: Medvi went from $20K to $1.8B annualized — the infrastructure works
- 3$22K is all it takes: telehealth-as-a-service + AI tools = near-zero startup cost
- 4Men who train are the best customers: high LTV, protocol adherence, word-of-mouth
- 5Dubai 0% tax: every dollar of profit compounds faster than US-based competitors
- 6No investors needed: profitable by month 8-10, then growth funds itself
- 7Optional vertical integration at $10M+: own pharmacy drops COGS from 25% to 10%